Hepatic disease / Liver disease

Efficacy parameters relevant to liver diseases: BMI, ALT, AST, gamma-GT, CHOL, HDL-c, LDL-c, TAG, CRP, TNF-alfa

Liver diseases pose a significant global health challenge, leading to approximately 2 million deaths annually. The primary drivers of these fatalities are cirrhosis, viral hepatitis, and hepatocellular carcinoma (HCC) (Devarbhavi et al. 2022 J. Hepatol. 79: 516-537). These conditions are intricately linked to both innate and adaptive immunity, with elevated systemic inflammation and immune dysfunction being the main triggers of hepatic tissue injury (Albillos et al. 2014 J. Hepatol. 61: 1385-1396)

Liver disease encompasses pathologies as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, alcohol liver disease, hepatocellular carcinoma, viral hepatitis, and autoimmune hepatitis.
Plaza-Díaz et al. 2020

Regarding liver diseases a reduced abundance of taxa considered benign, such as Lachnospiraceae, Ruminococcaceae and Clostridiales / Eubacteriales and a higher abundance of non-beneficial taxa such as Enterobacteriaceae and Bacteriodaceae were observed
Bajaj et al. 2014 J Hepatol 60: 940-947
Chen et al. 2015 J Gastroenterol Hepatol 30: 1429-37

T cell -mediated liver diseases , including autoimmune and viral hepatitis , are associated with significant morbidity and mortality worldwide and represent a serious concern in the clinical setting
McFarlane 1999 Biomed. Pharmacother. 53: 255-263
Diao et al. 2001 Cytokine Growth Factor Rev. 12: 189-205

The Con A-induced hepatitis in mice is a model of T cell-mediated liver diseases
Tiegs et al. 1992 J. Clin. Invest. 90: 196-203

see also:
Innate-like T cells (ILTCs)